Medicare Enrolled

Dr. Robert Mennel, MD

Medical Oncology · Dallas, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
3410 WORTH ST, Dallas, TX 75246
2143701000
In practice since 2006 (19 years)
NPI: 1265475677 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Mennel from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mennel? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Mennel

Dr. Robert Mennel is a medical oncology specialist in Dallas, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Mennel performed 26,788 Medicare services across 451 unique beneficiaries.

Between the years covered by Open Payments, Dr. Mennel received a total of $401 from 10 pharmaceutical and/or device companies across 22 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Mennel is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 32% volume in TX $401 industry payments

Medicare Practice Summary

Medicare Utilization ↗
26,788
Medicare services
Top 32% in TX for medical oncology
451
Unique beneficiaries
$1
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,410 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Iron sucrose injection (Venofer) 9,800 $0 $2
Iron infusion (Feraheme) 9,690 $0 $5
MRI contrast dye injection (gadobutrol) 3,200 $0 $2
Contrast dye for imaging (iodine-based) 2,951 $0 $3
Dexamethasone injection (steroid) 500 $0 $1
Injection, granisetron hydrochloride, 100 mcg 230 $0 $24
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 59 $51 $313
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less 58 $23 $157
Administration of chemotherapy into vein, 1 hour or less 51 $104 $707
Comprehensive metabolic blood panel 43 $10 $64
Blood draw (venipuncture) 41 $8 $20
Complete blood count (CBC) with differential 41 $7 $36
Ct scan of chest with contrast 31 $51 $821
CT scan of abdomen and pelvis with contrast 27 $184 $1,067
Administration of additional new drug or substance into vein, 1 hour or less 22 $51 $344
Injection of additional new drug or substance into vein 17 $12 $108
Mri scan of brain before and after contrast 15 $163 $3,085
Mri scan of abdomen before and after contrast 12 $203 $3,181
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
36.6% high complexity
62.8% medium
0.5% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$401
Total received (2020-2024)
Avg $100/year across 4 years
Bottom 20% in TX for medical oncology
10
Companies
22
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$389 (97.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$12 (3.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$44
2022
$95
2021
$182
2020
$80

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Incyte Corporation
$110
AstraZeneca Pharmaceuticals LP
$98
Takeda Pharmaceuticals U.S.A., Inc.
$43
Epizyme, Inc.,
$40
Rigel Pharmaceuticals, Inc.
$28
Dova Pharmaceuticals
$23
Blueprint Medicines Corporation
$20
Taiho Oncology, Inc.
$14
GlaxoSmithKline, LLC.
$13
Gilead Sciences, Inc.
$12
Top 3 companies account for 62.5% of total payments
Associated products mentioned in payments ›
AYVAKIT · BLENREP · Doptelet · IMFINZI · JAKAFI · LONSURF · LYNPARZA · MONJUVI · NINLARO · TAGRISSO · TAZVERIK · Tavalisse
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $2 per 100 Medicare services performed
Looking for a medical oncology specialist in Dallas?
Compare medical oncologists in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists within 10 mi
90
Per 100K population
3.5
County median income
$74,149
Nearest hospital
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data ✓ Medicare Util. Annual (CY lag)
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Mennel is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Mennel experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Mennel performed 9,800 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mennel receive payments from pharmaceutical companies?
Yes. Dr. Mennel received a total of $401 from 10 companies across 22 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mennel's costs compare to other medical oncologists in Dallas?
Dr. Mennel's average Medicare payment per service is $1. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mennel) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Medical Oncologists in Dallas
Browse medical oncologists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →